Vitae Pharmaceuticals Inc (NASDAQ:VTAE) has been downgraded to Neutral in a report by Piper Jaffray Cos. today.
- Updated: September 20, 2016
Having a price of $20.85, Vitae Pharmaceuticals Inc (NASDAQ:VTAE) traded 0.14% higher on the day. The last stock price is up 139.29% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the date range. Vitae Pharmaceuticals Inc has recorded a 50-day average of $9.66 and a two hundred day moving average of $8.73. 878,811 shares of the stock traded hands, down from an average trading volume of 950,048
Piper Jaffray Cos. has downgraded Vitae Pharmaceuticals Inc (NASDAQ:VTAE) to Neutral in a statement released on Tuesday September 20, 2016.
With a market capitalization of $0, Vitae Pharmaceuticals Inc has with a 52 week low of $4.08 and a 52 week high of $20.97 .
In addition to Piper Jaffray Cos. reporting its target price, a total of 5 equity analysts have released a ratings update on VTAE. The consensus target price is $16.60 with three brokerages rating the stock a strong buy, 2 analysts rating the company a buy, zero analysts rating the company a hold, zero equity analysts rating the stock a underperform, and finally 0 firms rating the stock a sell.
General Information About Vitae Pharmaceuticals Inc (NASDAQ:VTAE)
Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.